Cargando…

Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials

BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor ligand, has shown survival benefits in the treatment of many types of malignant tumors, including non-small-cell lung cancer (NSCLC). We conducted this systematic review and meta-analysis to investigate the ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Xi-Xi, Xu, Ren-Ai, Yu-Ping, Li, Yang, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844428/ https://www.ncbi.nlm.nih.gov/pubmed/27143937 http://dx.doi.org/10.2147/OTT.S96156

Ejemplares similares

Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Lima, André Bacellar Costa, et al.
Publicado: (2011)

Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials
por: Shin, Sooyoung, et al.
Publicado: (2018)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2011)

Efficacy and safety of bevacizumab combined with EGFR‐TKIs in advanced non‐small cell lung cancer: A meta‐analysis
por: Yang, Yifan, et al.
Publicado: (2021)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
por: Lee, Shu-Ping, et al.
Publicado: (2019)

Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma
por: Chen, Jianxin, et al.
Publicado: (2020)

An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients
por: Huang, Hongxin, et al.
Publicado: (2014)

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017)

Adverse events of intestinal microbiota transplantation in randomized controlled trials: a systematic review and meta-analysis
por: Chen, Chong, et al.
Publicado: (2022)

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials
por: Zhang, Weidong, et al.
Publicado: (2021)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer
por: Zhu, Yan-Juan, et al.
Publicado: (2017)

Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
por: Chen, Jian, et al.
Publicado: (2015)

The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Zhou, Yue, et al.
Publicado: (2021)

New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors
por: Lin, Xuwen, et al.
Publicado: (2023)

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
por: Loupakis, Fotios, et al.
Publicado: (2010)

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials
por: Yin, Xiaonan, et al.
Publicado: (2018)

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
por: Ngo, Doan T. M., et al.
Publicado: (2020)

Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system
por: Bai, Shuai, et al.
Publicado: (2021)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis
por: Liang, Ping, et al.
Publicado: (2020)

Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma
por: Zhang, Hui-Jie, et al.
Publicado: (2018)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
por: Zhao, Zhiting, et al.
Publicado: (2023)

Bevacizumab treatment for advanced non-small cell lung cancer: A case report
por: FAN, YUN, et al.
Publicado: (2013)

Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis
por: Wang, Wei, et al.
Publicado: (2014)

Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients
por: Totzeck, Matthias, et al.
Publicado: (2017)

Adverse events associated with acupuncture: three multicentre randomized controlled trials of 1968 cases in China
por: Zhao, Ling, et al.
Publicado: (2011)

Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
por: Li, Xiaofei, et al.
Publicado: (2018)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

Strengths and Weaknesses of Immunotherapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of 12 Randomized Controlled Trials
por: Wang, Juan, et al.
Publicado: (2012)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Combination of bevacizumab and photodynamic therapy vs. bevacizumab monotherapy for the treatment of wet age-related macular degeneration: A meta-analysis of randomized controlled trials
por: Wei, Qingquan, et al.
Publicado: (2018)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Ahmadizar, Fariba, et al.
Publicado: (2015)

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
por: Li, Xiaoqing, et al.
Publicado: (2015)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ocl463k3hph5dltqe8o76ebcs1